Sarepta Therapeutics, Inc. SRPT Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sarepta Therapeutics, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sarepta Therapeutics, Inc.'s additional paid-in capital?
- Sarepta Therapeutics, Inc. (SRPT) reported additional paid-in capital of $6.08B in Q1 2026.
- How has Sarepta Therapeutics, Inc.'s additional paid-in capital changed year-over-year?
- Sarepta Therapeutics, Inc.'s additional paid-in capital increased by 4.7% year-over-year, from $5.8B to $6.08B.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s additional paid-in capital has grown at a 10.9% compound annual growth rate (CAGR), from $3.61B to $6.04B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.